CoChat
Sign Up
Cited by 158Ovarian function and disordersDiabetes, Cardiovascular Risks, and LipoproteinsGenetic and Kidney Cyst Diseases

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Metformin Effects on Clinical Features, Endocrine and Metabolic Profiles, and Insulin Sensitivity in Polycystic Ovary Syndrome: A Randomized, Double-Blind, Placebo-Controlled 6-Month Trial, Followed by Open, Long-Term Clinical Evaluation

Moghetti, Paolo, Castello, Roberto, Negri, Carlo, Tosi, Flavia, Perrone, Fabrizia, Caputo, Marco, Zanolin, Elisabetta, Muggeo, Michele·2000·Obstetrical & Gynecological Survey
DOI 10.1097/00006254-200006000-00019
Open this paper in CoChat — free account

Abstract

Insulin resistance is a common feature of polycystic ovary syndrome (PCOS) regardless of whether patients are obese. There is evidence that the associated hyperinsulinemia contributes to development of the condition, suggesting that insulin-sensitizing drugs, such as metformin, might have therapeutic value. Reduced serum androgen levels have been reported in women with PCOS who were given metformin. The present randomized, double-blind, placebo-controlled study evaluated a 6-month course of metformin in 23 women aged 18 to 35 years with PCOS but normal glucose tolerance. A large majority were overweight. Women were assigned to receive either placebo capsules or metformin in a daily dose of 500 mg the first week, 1000 mg the second, and 1500 mg (three 500-mg capsules) for the next 24 weeks. Eighteen of these women and 14 others then participated in an open trial of metformin, the dose being increased stepwise as in the double-blind phase. Insulin sensitivity was estimated by the euglycemic hyperinsulinemic glucose clamp technique. Serum levels of free testosterone declined significantly with metformin treatment in the double-blind study. Both groups had a slight fall in body mass index, and there was no substantial change in hirsutism scores. Only one patient required dose reduction because of an adverse reaction. Menstruation was significantly more frequent during metformin therapy. Treatment correlated with a lower serum 17-hydroxyprogesterone response to buserelin. Fasting…

Overview

Integrity signals

Registry

Crossref · 10.1097/00006254-200006000-00019

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Metformin reduces insulin resistance in type 2 diabetes and in adults and adolescents with PCOS when hyperinsulinaemic euglycaemic clamps are used.

    “Metformin clearly reduces insulin resistance in DM2and in adults and adolescents with PCOS when hyperinsulinaemic euglycaemic clamps were used (Moghetti et al. , 2000; Meyer et al. , 2007; Arslanian et al. , 2002).”

    From Metformin and lifestyle modification in polycystic ovary syndrome: systematic review and meta-analysis (2015) · cites this paper as Moghetti et al. , 2000

Citations

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Metadata

Authors
Moghetti, P., Castello, R., Negri, C., Tosi, F., Perrone, F., Caputo, M., Zanolin, E., & Muggeo, M.
Affiliations
University of Verona (IT)
ORCID
Venue
Obstetrical & Gynecological Survey
Publisher
Ovid Technologies (Wolters Kluwer Health)
Published
2000-06
Volume
55
Issue
6
Pages
365-366
ISSN
0029-7828 (ISSN-L)
DOI
10.1097/00006254-200006000-00019
OpenAlex
W2011754459
Cited by
158
References
4
Citations by year
2025: 3 · 2024: 6 · 2023: 6 · 2022: 10 · 2021: 14 · 2020: 3 · 2019: 5 · 2018: 9 · 2017: 9 · 2016: 4 · 2015: 3 · 2014: 3 · 2013: 2 · 2012: 5
FWCI
10.32
Type
journal article
Language
en
Open access
closed
Locations
Obstetrical & Gynecological Survey (publishedVersion)
Topics
  • Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic and Kidney Cyst Diseases
Keywords
metformin, polycystic ovary syndrome, insulin resistance, insulin sensitivity, hyperinsulinemia, free testosterone, androgen levels, menstrual cycle regularity, ovulation, buserelin, 17-hydroxyprogesterone, hirsutism, body mass index, HDL cholesterol, insulin-sensitizing drugs, long-term follow-up, women of reproductive age

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review